ReviewFrontiers in neuroscience2023
Advances in diagnosing mild cognitive impairment and Alzheimer's disease using
Review in Frontiers in neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- RDoC-informed explainable AI as a paradigm for multilevel Alzheimer's disease diagnosis and progression prediction: a systematic review.Brain informatics · 2026Review
- Applying Multiple Machine Learning Models to Classify Mild Cognitive Impairment from Speech in Community-Dwelling Older Adults.Journal of Intelligence · 2026Article
- The Vibrational Signature of Alzheimer's Disease: A Computational Approach Based on Sonification, Laser Projection, and Computer Vision Analysis.Biomimetics (Basel, Switzerland) · 2025Article
- Planning care for nursing-home residents: cognitive impairment, functional independence, and accommodation services in nursing homes in the city of Zagreb.Croatian medical journal · 2025Article
- A Systematic Review of Natural Language Processing Techniques for Early Detection of Cognitive Impairment.Mayo Clinic proceedings. Digital health · 2025Review
- Recent Breakthroughs in PET-CT Multimodality Imaging: Innovations and Clinical Impact.Bioengineering (Basel, Switzerland) · 2024Review
- The novel imaging methods in diagnosis and assessment of cerebrovascular diseases: an overview.Frontiers in medicine · 2024Review
- Patterns of longitudinal subcortical atrophy over one year in amnestic mild cognitive impairment and its impact on cognitive performance: a preliminary study.Turkish journal of medical sciences · 2024Article
- Two decades of [American journal of nuclear medicine and molecular imaging · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a critical health issue worldwide that has a negative impact on patients' quality of life, as well as on caregivers, society, and the environment. Positron emission tomography (PET)/computed tomography (CT) and neuropsychological scales can be used to identify AD and mild cognitive impairment (MCI) early, provide a differential diagnosis, and offer early therapies to impede the course of the illness. However, there are few reports of large-scale
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.